Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16186542.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Among 27 preclinical carriers of the Huntington disease mutation (PMC), the authors found normal striatal values for MRI volumetry in 88% and for fluorodesoxyglucose PET metabolic index in 67%. Raclopride PET binding potential (RAC-BP) was decreased in 50% and correlated with increases in the product of age and CAG repeat length (p < 0.0005). Dopamine D2 receptor availability measured by RAC-BP seems the most sensitive indicator of early neuronal impairment in PMC.
Medical subject headings
- Corpus Striatum
- Dopamine
- Huntington Disease
- Receptors, Dopamine D2